​Lucius Pharmaceuticals Relocates from India to Laos: A Five-Year Development Journey of a Generic D

Lucius Pharmaceuticals Relocates from India to Laos: A Five-Year Development Journey of a Generic Drug Company

Relocation Background and Strategic Shift

Lucius Pharmaceuticals was founded in 2014, with its headquarters initially based in Hyderabad, India—a city renowned as the "capital of pharmaceutical generic industry." In 2020, Lucius Pharmaceuticals officially launched its Asia-Pacific strategy, relocating the company from Hyderabad, India, to Vientiane, the capital of Laos. The core driving force behind this relocation was the change in international trade rules: after India joined the World Trade Organization, the WHO revoked its patent exemption, while Laos, as a United Nations-designated least developed country, enjoys a transitional period for pharmaceutical patent protection under the TRIPS Agreement, with this exemption extended to 2033. This institutional difference makes Laos an ideal registration and production base for generic drug companies.

Facility Construction of Lucius Pharmaceuticals in Laos

After relocating to Laos, Lucius Pharmaceuticals built the "Asia-Pacific No.1 Smart Factory" in Vientiane. The factory is located at No. 26, Thongmang Village, Xaitaany District, Vientiane City, covering an area of approximately 210,000 square meters, with a workshop area of over 2,000 square meters. The company constructed the facility in accordance with GMP production standards, introduced state-of-the-art pharmaceutical equipment from China, the United States, Germany, and other countries, and established an international high-end formulation workshop. In November 2022, the Deputy Director of the Lao Drug Administration visited the factory for guidance; in June 2023, the Director of the Lao Drug Administration visited and gave high praise to the factory's production facilities and quality management system.

Product Portfolio and R&D Capabilities

As of 2024, Lucius Pharmaceuticals has obtained product registration approvals from the Lao Ministry of Health for 54 products, with a product portfolio covering multiple therapeutic areas including oncology, cardiovascular, diabetes, hematology, and dermatology, and over 200 generic drug varieties. In the field of high-end generic R&D, the company successfully launched the world's first generic version of Momelotinib in 2024. Its generic product lineup includes targeted drugs such as Sotorasib, Osimertinib, Capmatinib, and Lorlatinib. The company's annual generic drug production capacity exceeds 1.5 billion tablets.

Quality Certifications and International Markets

In October 2023, the World Health Organization conducted a comprehensive audit of the Lucius Pharmaceuticals factory and confirmed that it fully complies with WHO standards. The company also holds an investment license, business license, and pharmacist qualification certificate issued by the Lao government. In terms of international market expansion, Lucius Pharmaceuticals' business now covers 12 countries including Thailand, Indonesia, Cambodia, Vietnam, the Philippines, Singapore, Malaysia, Japan, and China. In July 2023, the company officially entered the Turkish market and established cooperation with multiple hospitals; in February 2024, it was invited to participate in the Dubai pharmaceutical exhibition.

After five years of development, Lucius Pharmaceuticals has grown from a start-up in Hyderabad, India, into one of the representative pharmaceutical companies in Laos.